期刊文献+

前列腺癌骨转移患者血清ODF、OCIF含量及临床价值评估 被引量:4

Detection of serum ODF and OCIF contents in prostate cancer patients with bone metastasis and its clinical value assessment
下载PDF
导出
摘要 目的:研究前列腺癌骨转移患者血清ODF、OCIF含量及其临床价值。方法:采集前列腺癌骨转移骨转移和非骨转移患者的血清,检测ODF、OCIF含量;培养前列腺癌DU145细胞,用不同浓度的ODF、OCIF处理后,检测细胞迁移率以及LASS-2/TMSG-1的mRNA含量。结果:骨转移组血清中ODF、OCIF的含量以及ODF/OCIF的比值均高于非骨转移组(P<0.05);骨转移病灶数目越多,血清ODF含量越高、而OCIF含量越低;ODF处理能够剂量依赖性地增加前列腺癌细胞迁移率、减少LASS-2/TMSG-1的mRNA含量;OCIF处理能够剂量依赖性地降低前列腺癌细胞迁移率、增加LASS-2/TMSG-1的mRNA含量。结论:前列腺癌骨转移患者血清中ODF、OCIF含量均升高,且以ODF升高的效应更为明显;ODF具有促进前列腺癌细胞迁移的作用、而OCIF具有抑制作用。 Objective:To detect serum ODF and OCIF contents in prostate cancer patients with bone metastasis and its clinical value.Methods:Serum of prostate cancer patients with and without bone metastasis was collected,then ODF and OCIF contents were detected;prostate cancer DU145 cells were cultured and treated with different concentrations of ODF and OCIF,then cell migration rates as well as mRNA contents of LASS-2/TMSG-1were detected.Results:Serum ODF and OCIF contents as well as ODF/OCIF ratio of bone metastasis group were all higher than those of non-bone metastasis group;the more the number of metastatic bone lesions was,the higher the serum ODF content was,and the lower the OCIF content was;ODF treatment could increase prostate cancer cell migration rates and decrease mRNA contents of LASS-2/TMSG-1on dose-dependent manner;OCIF treatment could decrease prostate cancer cell migration rates and increase mRNA contents of LASS-2/TMSG-1on dose-dependent manner.Conclusion:Serum ODF and OCIF contents in prostate cancer patients with bone metastasis increase,and ODF increase effect is more obvious;ODF has promoting effect on prostate cancer cell migration while OCIF has inhibiting effect.
出处 《海南医学院学报》 CAS 2015年第12期1690-1692,1696,共4页 Journal of Hainan Medical University
基金 湖北省科技计划项目(2012JK2056)~~
关键词 前列腺癌 骨转移 破骨细胞 细胞迁移 Prostate cancer Bone metastasis Osteoclast differentiation factor Osteoclastogenesis inhibitory factor Migration
  • 相关文献

参考文献15

  • 1KushlinskiǐNE,TimofeevIuS,Gershteǐn ES,et al.Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].VoprOnkol,2014,60(4):413-421.
  • 2李莉,刘志武,谭榜云,陈明,张艺.肺癌患者血清ODF和OCIF水平与骨转移的相关性研究[J].中国肿瘤临床,2013,40(15):898-901. 被引量:2
  • 3Li X,Liu Y,Wu B,et al.Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis[J].Oncol Rep,2014,32(6):2605-2611.
  • 4Miller RE,Jones JC,Tometsko M,et al.RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases[J].J ThoracOncol,2014,9(3):345-354.
  • 5Chu GC,Chung LW.RANK-mediated signaling network and cancer metastasis[J].Cancer Metastasis Rev,2014,33(2-3):497-509.
  • 6Wang J,Chen TY,Qin S,et al.Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system[J].Med Hypotheses,2013,81(5):805-806.
  • 7Pneumaticos SG,Christofides A,Gkioka E,et al.Osteoprotegerin expression during the micro-and macrometastatic phases of the osteoblastic metastasis in prostate cancer:therapeutic implications[J].Expert OpinTher Targets,2013,17(12):1395-1403.
  • 8谭云昌.血清破骨细胞分化因子及生成抑制因子测定在前列腺癌骨转移诊断中的价值[J].中国现代医学杂志,2014,24(1):37-40. 被引量:6
  • 9Sakamoto S,Ichikawa T.Mechanism of prostate cancer invasion and metastasis[J].Nihon Rinsho,2014,72(12):2086-2089.
  • 10Rafiei S,Komarova SV.Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells[J].BMC Cancer,2013,26(13):605.

二级参考文献26

  • 1Khosla S. Minirevicw: the OPG/RANKL/hRANK system[J]. Endocrinology, 2001, 142 (12) :5050-5055.
  • 2Lacey DL, Tinmas E, Tan HL, et al. Osteoprotegcrin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell, 1998, 93(2):165-176.
  • 3Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoproteg crin ligand[J] Nature, 1999, 402 (6759) :304-309.
  • 4Walsh MC, Choi Y. Bioiogy of the TRANCE axis[J]. Cytokine Growth Factor Rew, 2003, 14(3-4):251-263.
  • 5Hofbauer LG, Khosla S, Dunstan CR, et al. The rols of osteoprote- gerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res, 2000, 15(1):2-12.
  • 6Nishimura M, Yuasa K, Mori K, et al. Cytolgical properties of stro- real cells derived From giant cell tumor of bone(GCTSC) which can induce osteoclast formation of human biood monocytes with- out cell to cell contact[J].J Orthop Res, 2005, 23 (5):979-987.
  • 7Kumanoto H, Ooya K. Expression of parathyroid hormone- relat- ed protein (PTHrP),osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclas- togenesis inhibitory factor (OCIF)/osteoprotegerin (OPG)in amclo- blastomas[J]. J Oral Pathol Med, 2004, 33 (1):46-52.
  • 8Koide M, Murase Y, Yamato K, et al. Bone morphogenetie protein-2 enhances osteoclast formation mediated by interleukin-lalpha through upregulation of osteoclast differentiation factor and cydooxygenase-2 [J]. Biochem Biophys Res Commun, 1999, 259(1):97-102.
  • 9Body JJ. Metastic bone disease: clinical and therapeutic aspects[J]. Bone, 1992, 13(Suppl 1):S57-62.
  • 10Coleman RE, Mashiter G, Whitaker KB, et al. Bone scan flare predicts successful systemic therapy for bone metastases[J].J Nucl Med, 1988, 29(8):1354-1359.

共引文献6

同被引文献39

  • 1Ferreira S,Dormehl I,Botelho MF.Radiopharmaceuticals for bone metastasis therapy and beyond:a voyage from the past to the present and a look to the future[J].Cancer Biother Radiopharm,2012,27(9):535-551.
  • 2Safarzadeh L.(175)Yb-TTHMP as a good candidate for bone pain palliation and substitute of otherradiopharmaceuticals[J].Indian J Nucl Med,2014,29(3):135-139.
  • 3Fallon M,Hoskin PJ,Colvin LA,et al.Randomized DoubleBlind Trial of Pregabalin Versus Placebo in Conjunction With PalliativeRadiotherapy for Cancer-Induced Bone Pain[J].J Clin Oncol,2016,34(6):550-556.
  • 4Sande TA,Scott AC,Laird BJ,et al.The characteristics of physical activity and gait in patients receiving radiotherapy in cancer inducedbone pain[J].Radiother Oncol,2014,111(1):18-24.
  • 5Ayan AK,Erdemci B,Orsal E,et al.Is there any correlation between levels of serum ostepontin,CEA,and FDG uptake in lung cancerpatients with bone metastasis?[J].Rev Esp Med Nucl Imagen Mol,2016,35(2):102-106.
  • 6da Silva GT,Bergmann A,Thuler LC.Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer[J].Support Care Cancer,2016,24(2):731-736.
  • 7Tamiya M,Tokunaga S,Okada H,et al.Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer:A Prospective Study[J].Anticancer Res,2015,35(7):3987-3993.
  • 8Imataki O,Uchida S,Shiroshita K,et al.Marked Hematopoiesis Masquerading Multiple Bone Metastasis in a Lung Cancer Patient With Myelodysplastic Syndrome[J].Clin Nucl Med,2015,40(7):574-575.
  • 9陈旭,王琳,蒋敏,史进方,马海涛,顾国浩.肺癌患者血清和单个核细胞9种miRNAs表达差异及其意义[J].中华检验医学杂志,2013,36(2):165-172. 被引量:13
  • 10肖黎,金艳阳,佟明.miRNA-21对其靶基因PTEN在前列腺癌中表达调控机制的研究[J].现代预防医学,2013,40(6):1112-1115. 被引量:6

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部